ArticleFrontiers in medicine2026
Risk factors for metachronous esophageal squamous cell carcinoma after endoscopic submucosal dissection: a multicenter cohort study integrating overall risk prediction and timing of recurrence.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endoscopic submucosal dissection (ESD) has become the standard of care for superficial esophageal squamous cell carcinoma (ESCC). Nevertheless, the persistence of field cancerization leaves patients vulnerable to metachronous lesions, underscoring an urgent need for reliable post-ESD surveillance strategies. We reasoned that a refined risk stratification approach might optimize personalized follow-up. Aim: This study therefore aimed to identify independent predictors of metachronous ESCC after curative ESD and, secondarily, to explore factors distinguishing early from late recurrence among those who relapse. Methods: We conducted a retrospective multicenter cohort study involving 1,646 patients with curative ESD for superficial ESCC across two Chinese tertiary centers between 2014 and 2024. For the primary endpoint, we employed Cox proportional hazards regression to identify variables associated with overall metachronous recurrence. In a separate exploratory analysis restricted to the 192 patients who actually developed recurrence, we applied logistic regression to examine determinants of early recurrence (defined as ≤36.7 months, the median time to recurrence) vs. late recurrence (>36.7 months). Results: During a median follow-up of 68.6 months, 192 patients (11.7%) experienced metachronous ESCC. In the primary Cox model based on a parsimonious set of 8 variables selected via LASSO regression, the strongest predictor was high-risk Lugol pattern (type C/D vs. A/B: HR = 18.868, 95% CI: 12.494-28.495), followed by elevated white blood cell count (per 1 × 10 Conclusion: Our findings indicate that endoscopic features-particularly Lugol pattern-dominate the prediction of overall metachronous recurrence risk. The exploratory early vs. late recurrence analysis suggests that systemic inflammatory (WBC) and nutritional/metabolic (macrocytosis) parameters may modulate recurrence timing, but these findings are hypothesis-generating and require external validation before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.